Angewandte
Chemie
DOI: 10.1002/anie.201402170
Synthetic Methods
Construction of Chiral Bridged Tricyclic Benzopyrans:
Enantioselective Catalytic Diels–Alder Reaction and a One-Pot
Reduction/Acid-Catalyzed Stereoselective Cyclization**
Aiguo Song, Xishuai Zhang, Xixi Song, Xiaobei Chen, Chenguang Yu, He Huang, Hao Li,* and
Wei Wang*
Abstract: An asymmetric two-step approach to chiral bridged
tricyclic benzopyrans, core structures featured in various
natural products, is described. In the synthesis, an unprece-
dented enantioselective catalytic decarboxylative Diels–Alder
reaction is developed using readily available coumarin-3-
carboxylic acids and aldehydes as reactants under mild
reaction conditions. Notably, the decarboxylation-assisted
release of the catalyst enables the process to proceed efficiently
with high enantio- and diastereoselectivity. Furthermore, a one-
pot procedure for either a LiAlH4- or NaBH4-mediated
reduction with subsequent acid-catalyzed intramolecular cyc-
lization of the Diels–Alder adducts was identified for the
efficient formation of the chiral bridged tricyclic benzopyrans.
Figure 1. The bridged tricyclic benzopyran core unit A found in natural
products.
T
he discovery of powerful simplifying transformations for
rapid access to the core structures featured in natural
products is a central goal of organic synthesis. The bridged
tricyclic benzopyran framework A is present in a fascinating
array of structurally diverse and biologically intriguing
complex natural products such as cannabinoid,[1] oxabicyclo-
nonane, murrayamines D and cyclomahanimbine,[2] and
kuwanol B (Figure 1),[3] sanggenone R,[4a] mulberrofurans I
and S and sorocenol B,[4b] and saustralisin B,[4c] mongol-
icin C,[4d] and isorubraine, etc.[4e] The construction of the
bridged scaffold requires installing two contiguous chiral
centers, including one quaternary center. Typically, this
substructure is built through acid-catalyzed cyclizations of
phenolic alkene precursors.[5] However, asymmetric synthesis
of the scaffolds remains elusive. To the best of our knowledge,
only a single study was reported by Yao and co-workers
describing a binary Pd(OAc)2 and (S)-Trip system to catalyze
an enantioselective annulation process between 2-hydroxy-
styrenes and 2-alkynylbenaldehyes or 1-(2-alkynylphenyl)ke-
tones.[6] To streamline substantial advances in this arena, new
catalytic asymmetric methodologies using simple substances
are more appealing.
Herein, we report an efficient two-step access to the chiral
complex molecular architecture (Scheme 1). A novel catalytic
enantioselective Diels–Alder reaction of readily available
coumarin-3-carboxylic acids (2) with aldehydes (1) is
designed.[7] The carboxylic moiety not only enhances the
reactivitity of coumarins as dienophiles, but also facilitates the
release of the amine catalyst.[8] Different from the reported
studies in aminocatalytic Diels–Alder reactions where the
dienophiles contain a prerequisite a-hydrogen atom, which is
essential for the release of the amine catalyst,[9] a novel
catalyst release mode by decarboxylation was uncovered.
Importantly, the decarboxylation-assisted release of the
catalyst enables the Diels–Alder reaction to proceed effi-
ciently (short reaction times and high yields) under mild
reaction conditions with high enantio- and diastereoselectiv-
ity. Moreover, a new one-pot protocol involving either
a LiAlH4- or NaBH4-mediated reduction and subsequent
acid-catalyzed intramolecular stereoselective cyclization of
the Diels–Alder adducts was identified for the efficient
formation of the chiral bridged tricyclic benzopyran 8. The
cyclization involves an interesting phenolic attack of the diene
moiety driven by dehydration of the allylic alcohol in 6
(Scheme 1).
[*] A.-G. Song, Dr. X.-S. Zhang, X.-X. Song, X.-B. Chen, C.-G. Yu,
H. Huang, Prof. Dr. W. Wang
Department of Chemistry & Chemical Biology
University of New Mexico, Albuquerque, NM 87131 (USA)
E-mail: wwang@unm.edu
Prof. Dr. H. Li, Prof. Dr. W. Wang
State Key Laboratory of Bioreactor Engineering and
Shanghai Key Laboratory of New Drug Design
East China University of Science & Technology
Shanghai 200237 (China)
E-mail: hli77@ecust.edu.cn
info28553.htm
[**] Financial support from the NSF (CHE-1057569) and the National
Science Foundation of China (No. 21372073) is gratefully
acknowledged.
Supporting information for this article is available on the WWW
Angew. Chem. Int. Ed. 2014, 53, 1 – 6
ꢀ 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
1
These are not the final page numbers!